BrightPath Biotherapeutics Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
BrightPath Biotherapeutics Co., Ltd. carries a market capitalization of 5.09B, placing it among publicly traded companies globally.
| Market Cap | 5.09B |
| Enterprise Value | N/A |
Share Statistics
BrightPath Biotherapeutics Co., Ltd. currently has 70.74M shares outstanding.
| Shares Outstanding | 70.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 58,523.75, and the price-to-book ratio stands at -2.10.
| PE Ratio | N/A |
| PS Ratio | 58,523.75 |
| PB Ratio | -2.10 |
| P/TBV Ratio | 4.30 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
BrightPath Biotherapeutics Co., Ltd. maintains a current ratio of 6.18, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.18 |
| Quick Ratio | 5.54 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -79.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.90M |
| Effective Tax Rate | N/A |
Stock Price Statistics
BrightPath Biotherapeutics Co., Ltd.'s stock has gained approximately 33.33333% over the past 52 weeks. The 50-day moving average sits at 60.24, while the 200-day moving average is 63.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | 33.33333% |
| 50-Day Moving Average | 60.24 |
| 200-Day Moving Average | 63.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BrightPath Biotherapeutics Co., Ltd. generated 72,000.00 in revenue and converted that into -1.17B in net income, yielding earnings per share of -18.57. EBITDA reached -1.16B, while operating income came in at -1.16B.
| Revenue | 72,000.00 |
| Gross Profit | 54,000.00 |
| Operating Income | -1.16B |
| Pretax Income | -1.17B |
| Net Income | -1.17B |
| EBITDA | -1.16B |
| EBIT | -1.16B |
| Earnings Per Share (EPS) | -18.57 |
Balance Sheet
Total book value stands at -2.00B, with working capital of 989.95M providing operational flexibility.
| Cash & Cash Equivalents | 1.06B |
| Total Debt | N/A |
| Net Debt | -944.86M |
| Equity (Book Value) | -2.00B |
| Book Value Per Share | -31.85 |
| Working Capital | 989.95M |
Margins
BrightPath Biotherapeutics Co., Ltd. operates with a gross margin of 75.00, reflecting its pricing power and cost economics. The operating margin of -1.60M and net profit margin of -1.62M provide insight into operational efficiency.
| Gross Margin | 75.00 |
| Operating Margin | -1.60M |
| Pretax Margin | -1.62M |
| Profit Margin | -1.62M |
| EBITDA Margin | -1.60M |
Scores
BrightPath Biotherapeutics Co., Ltd. posts an Altman Z-Score of 4.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.91 |